Pharma Deals That Generate Lasting Value: A Roundtable Discussion
Executive Summary
At Elsevier Business Intelligence's recent Therapeutic Area Partnerships conference, a roundtable of senior pharmaceutical executives and entrepreneurs weighed in on industry’s current funding challenges, how dealmaking defines a biotech’s ambitions and strategy, and pharma’s appetite for early-stage innovation.
You may also be interested in...
Aileron Overcoming Spirited Debate About Stapled Peptides
The new, promising class of drugs is rolling toward the clinic, but a respected research group recently thrust a stick in the spokes and prompted a call for wider access to the technology.
Pursuit Of R&D Efficiency Continues As Regulatory Options Expand In 2013 – Tufts CSDD
Cutting non-core procedures – such as those supporting exploratory endpoints – from study budgets could save the industry $6 billion a year in drug development costs, the Tufts Center for the Study of Drug Development suggests in its 2013 industry outlook report.
With Dueling Papers Comes A Spirited Debate About Stapled Peptides
The new, promising class of drugs is rolling toward the clinic, but a respected research group recently thrust a stick in the spokes and prompted a call for wider access to the technology.